Welcome to our dedicated page for Rxsight news (Ticker: RXST), a resource for investors and traders seeking the latest updates and insights on Rxsight stock.
RxSight, Inc. develops and sells ophthalmic medical technology for customized vision after cataract surgery. Its RxSight Light Adjustable Lens system includes Light Adjustable Lens products, the Light Delivery Device and related accessories, enabling post-operative adjustment of an intraocular lens based on patient visual feedback.
RxSight news commonly covers financial results, sales guidance, Light Adjustable Lens unit demand, Light Delivery Device placements and installed-base growth. Company updates also address clinical evidence presented in cataract and refractive surgery forums, regulatory approvals in international markets, healthcare conference participation and executive finance leadership changes.
Summary not available.
Summary not available.
Summary not available.
RxSight, Inc. (NASDAQ: RXST), a company focused on advanced ophthalmic medical devices, is set to present at the Bank of America Healthcare Conference on May 10, 2023, at 3:55 PM PT / 6:55 PM ET. The presentation will focus on their innovative RxSight® Light Adjustable Lens system, which enhances vision after cataract surgery by allowing adjustments post-operatively. This system includes the RxSight Light Adjustable Lens® and the Light Delivery Device (LDD™), marking it as the first adjustable intraocular lens technology available. Interested stakeholders can access the live and archived webcast of the presentation via the company’s investor relations website.
RxSight, Inc. (NASDAQ: RXST) announced that it will report its first quarter 2023 financial results on May 9, 2023, after market close. Management is set to discuss the results during a conference call beginning at 1:30 PM PT / 4:30 PM ET. This call aims to provide insights into the company’s financial performance and future outlook following their innovative advancements in ophthalmic medical devices, specifically their Light Adjustable Lens system designed for cataract surgery. The technology is unique as it allows for post-surgery adjustments to optimize patients' vision quality. Interested investors can register for the call and access it via a live and archived webcast.
RxSight, Inc. (NASDAQ: RXST) announced that its Light Adjustable Lens™ (LAL) system will feature in various surgeon presentations at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from May 5-8, 2023. Key topics include:
- Presbyopia Correction - Neda Shamie, MD on May 5.
- Small Aperture Technology Integration - Cathleen M. McCabe, MD on May 6.
- Corneal Astigmatism Outcomes - Multiple presenters on May 7.
Surgeons will also share their LAL experiences at RxSight's booth (#1911), with additional details available through their website. This technology is the only adjustable intraocular lens system, enhancing post-cataract surgery vision.
On April 5, 2023, RxSight, operating under the stock symbol RXST, announced its participation in the Needham Healthcare Conference. The management team will engage in a fireside chat on April 19, 2023, at 11:15 a.m. PT, accessible via a live and archived webcast on their investor relations website.
RxSight is an ophthalmic medical device company focused on enhancing vision after cataract surgery with its innovative RxSight Light Adjustable Lens system. This technology allows for custom adjustments post-surgery, providing patients with optimized visual outcomes. For more details, visit www.rxsight.com.
RxSight, Inc. (NASDAQ: RXST) reported robust financial growth in its fourth quarter and full year 2022 results. Fourth quarter revenue reached $16.1 million, marking a 91% increase from 2021, driven by a 27% rise in Light Delivery Devices (LDDs) sold and a remarkable 208% jump in Light Adjustable Lenses (LALs). Full year revenue was $49.0 million, up 117% from 2021. The company anticipates 2023 revenue between $78.0 million and $83.0 million, signaling potential growth of 59% to 69%. Despite a net loss of $(66.8) million for 2022, the gross profit margin improved to 43.5%.
RxSight, Inc. is set to participate in the upcoming Oppenheimer Healthcare Conference on March 13, 2023, at 7:00 a.m. PT / 10:00 a.m. ET. The company specializes in ophthalmic medical devices focused on providing customized vision solutions following cataract surgery. Their innovative RxSight® Light Adjustable Lens (LAL®) system is the first intraocular lens technology allowing post-surgery adjustments to enhance patient vision quality. Interested parties can access a live and archived webcast of the presentation through their investor relations website.
RxSight, Inc. (NASDAQ: RXST) announced it will release its fourth quarter and fiscal year 2022 financial results on March 6, 2023, following market close. Management will hold a conference call at 1:30 p.m. PT to discuss the results. Interested participants can register for the call and access the live webcast on the company’s investor relations page.
RxSight specializes in ophthalmic medical devices and offers the innovative RxSight Light Adjustable Lens system, the first adjustable intraocular lens technology, enhancing patient vision post cataract surgery.